UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Investing offers numerous advantages compared to saving, including potential for higher returns. Explore the benefits of making your money work for you.
12,774 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
When a notable investor sells a stake in a popular dating platform, it can raise questions about the stock’s path for...
Rivian readies its lower-cost R2 for April deliveries, a pivotal move as analysts weigh its power to expand beyond pr...
What to expect from Kodiak’s 2025 earnings? This guide breaks down revenue drivers, margins, and realistic scenarios ...
Three sector ETFs are beating the Nasdaq tech index in 2026, signaling a shift toward defense tech, electrification, ...
Three stocks mispriced right could offer substantial upside for patient investors. This article breaks down why these...
Cryptio has closed a $45 million Series B to scale its enterprise crypto accounting platform, aiming to help large fi...
A sharp, near-$99 million exit from this cybersecurity stock has analysts buzzing about a possible shift in investor ...
A growing cohort of retirees is buying into the Taiwan-centric ETF EWT to capture gains from Taiwan’s chipmakers. The...
Renting property comes with big responsibilities. This article breaks down the four essential duties landlords must m...
The Ethereum Foundation has quietly moved 5,000 ETH to BitMine in a $10 million over-the-counter trade, marking its s...
Crypto swings may lift Coinbase, but the real upside comes from non crypto revenue streams. This guide explains why t...